Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predictor of clinical relapse among patients with ulcerative colitis

This month's issue of the American Journal of Gastroenterology explores histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis.

News image

fiogf49gjkf04
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."

Am J Gastroenterol 2016; 111:1692–1701
13 December 2016

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us